Digicann Ventures Valuation
Is VY3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VY3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VY3's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VY3's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VY3?
Key metric: As VY3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is VY3's PE Ratio? | |
|---|---|
| PE Ratio | 0.04x |
| Earnings | CA$11.62m |
| Market Cap | CA$441.11k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | -8.3x |
| Enterprise Value/EBITDA | -0.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does VY3's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.4x | ||
ECX Epigenomics | 0.4x | n/a | €1.3m |
CNNC Cannonau | 0.7x | n/a | US$241.8k |
SE Sweet Earth Holdings | 2.7x | n/a | CA$496.1k |
2FJ0 Pierrel | 29.9x | n/a | €92.8m |
VY3 Digicann Ventures | 0.04x | n/a | €441.1k |
Price-To-Earnings vs Peers: VY3 is good value based on its Price-To-Earnings Ratio (0x) compared to the peer average (8.4x).
Price to Earnings Ratio vs Industry
How does VY3's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: VY3 is good value based on its Price-To-Earnings Ratio (0x) compared to the European Pharmaceuticals industry average (20x).
Price to Earnings Ratio vs Fair Ratio
What is VY3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 0.04x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VY3's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Perrigo
US$3.9b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$26.89
7D
4.5%
1Y
-3.3%
Collegium Pharmaceutical
US$983.6m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
0%
1Y
23.9%
Almirall
€1.9b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.70
7D
4.9%
1Y
3.8%